Quantcast

Latest Influenza research Stories

2011-06-13 07:51:01

(Ivanhoe Newswire) -- In a new research article, Harvard scientists outline a variety of factors that influence vaccine production and access to those vaccines. Researchers say the technologies used to manufacture different types of vaccines affect cost and availability. Other factors such as different national regulations, shelf life, and cold chain requirements may also influence vaccine cost. For example, the researchers say the oral polio vaccine strains grow well in culture, which allows...

27a9e6dab4eb5b5173e479ad14868a9f
2011-06-09 05:05:00

The need to create a new flu vaccine annually could be eliminated with a universal influenza vaccine that targets a protein common to all strains of influenza A, which has been able to safely produce an immune response in humans, according to a study published in the journal Vaccine. If proven effective, it will have major implications for global health. Two studies were conducted, one at the University of Texas Medical Branch at Galveston (UTMB) and one at Johnson County Clin-Trials in...

2011-06-07 08:10:00

SAN FRANCISCO, June 7, 2011 /PRNewswire/ -- Vaxart, Inc., a San Francisco biotechnology company developing oral-delivery vaccines, has begun dosing volunteers in a Phase I clinical trial. This is the first clinical study evaluating a vaccine that uses the company's novel oral-vaccine platform technology. The trial site is in the United States. "This first trial in humans is important, because if safety is demonstrated with one vaccine, we can expect that later vaccines using the same...

2011-05-10 07:00:00

SWIFTWATER, Pa., May 10, 2011 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today the U.S. Food and Drug Administration (FDA) has approved the company's supplemental biologics license application (sBLA) for licensure of Fluzone Intradermal (Influenza Virus Vaccine). Fluzone Intradermal vaccine is indicated for active immunization of adults 18 through 64 years of age against influenza disease caused by influenza virus subtypes A and...

2011-05-09 07:00:00

ROCKVILLE, Md., May 9, 2011 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced its financial results for the first quarter ended March 31, 2011. The company reported a net loss of $7.5 million, or $0.07 per share, for the first quarter of 2011, compared to a net loss of $10.3 million, or $0.10 per share, for the first quarter of 2010. The primary reason for the decreased loss during the quarter was due to lower research and development spending to support clinical trials of the...

2011-04-29 11:00:00

-largest livestock vaccine manufacturing facility in Canada- BELLEVILLE, ON, April 29 /PRNewswire/ - Bioniche Life Sciences Inc. (TSX:BNC) (ASX:BNC), a research-based, technology-driven Canadian biopharmaceutical company, today officially opened its new Animal Health and Food Safety Vaccine Manufacturing Centre at its corporate headquarters in Belleville, Ontario, Canada. This facility represents the largest livestock vaccine manufacturing facility in Canada, with capacity to supply...

2011-04-05 07:00:00

ROCKVILLE, Md., April 5, 2011 /PRNewswire/ -- Novavax, Inc. (NASDAQ: NVAX) announced that its virus-like particle (VLP) influenza vaccine has been named by the editors of R&D Directions magazine as one of the top "100 great investigational drugs in development" today. In its tenth annual list of promising clinical compounds, R&D Directions cited Novavax's virus-like-particle technology as a promising new approach to producing vaccines to prevent seasonal, H1N1 and avian influenza....

2011-03-21 06:00:00

-The Company launches the clinical development of its seasonal flu vaccine- QUEBEC CITY, March 21 /PRNewswire-FirstCall/ - Medicago Inc. (TSX: MDG) a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that the first dose of vaccine has been administered thereby initiating the Company's phase I H1N1 influenza VLP vaccine candidate ("H1N1 vaccine")...

2011-03-21 03:00:00

BLUE BELL, Pa., March 21, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that it has received a U.S. Department of Defense Small Business Innovation Research Grant to test the feasibility of delivering DNA vaccines by intradermal electroporation simultaneously to two or more spatially distinct sites on the body. The purpose of such a prototype...

2011-02-28 18:30:00

ROCKVILLE, Md., Feb. 28, 2011 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) announced today an agreement to license its proprietary, recombinant virus-like-particle (VLP) vaccine technology to LG Life Sciences, Ltd. (LGLS). Under the agreement, LGLS receives an exclusive license to manufacture, develop and commercialize influenza vaccines using Novavax's recombinant VLP technology in South Korea. LGLS also receives a non-exclusive license to manufacture, develop and commercialize influenza...


Word of the Day
Cthulhu
  • A gigantic fictional humanoid alien god being described with a head resembling an octopus and dragon wings and claws, around whom an insane cult developed.
  • Pertaining to the mythos of Cthulhu and additional otherworldly beings created by H. P. Lovecraft or inspired by his writings and imitators.
This word was invented in 1926 by H.P. Lovecraft for his short story, 'The Call of Cthulhu.' 'Cthulhu' may be based on the word 'chthonic,' which in Greek mythology refers to the underworld.
Related